What is the 13F Pro Quality Score for TMDX?

13F Pro ranks TransMedics Group, Inc. (TMDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TMDX's current score at https://13fpro.ai/company/TMDX (free sign-up required for the full ranking).

Which hedge funds own the most TMDX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TMDX include BlackRock,, FMR, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TMDX as soon as new 13F filings post.

Where does 13F Pro source TMDX data?

All TransMedics Group, Inc. fundamentals and ownership data come directly from SEC EDGAR. TransMedics Group, Inc. files with the SEC under CIK 1756262. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TMDX in?

TransMedics Group, Inc. (TMDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives TMDX's revenue?

Per TransMedics Group, Inc.'s latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Net product revenue ($111.2M, +16% YoY); Service revenue ($78.8M, +29% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/TMDX.

What are TMDX's largest expenses?

TransMedics Group, Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($57.8M, +31% YoY); Total cost of revenue ($76.8M, +26% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is TMDX research updated on 13F Pro?

TMDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TransMedics Group, Inc.(TMDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1756262 TMDX stock profile & AI dashboard →

13F Pro Quality Score

67.2/100

Rank #377 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

92.1/100

Profitability

86.4/100

Balance Sheet

90.2/100

Earnings Quality

60.8/100

Free Cash Flow

59.5/100

Institutional Flow

25.6/100

Revenue Scale

41.9/100

Dilution Risk

22.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TMDX Scores 67/100

exact factor attribution · 2026-09-11

TMDX's composite is driven by revenue growth and profitability, held back by shareholder dilution and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.4 pts

92th pct

Profitability

+5.5 pts

86th pct

Capital efficiency

+4.0 pts

90th pct

Free cash flow

+1.4 pts

60th pct

Earnings quality

+1.1 pts

61th pct

Earnings growth

+0.7 pts

63th pct

Scale

-1.2 pts

42th pct

Institutional flow

-1.2 pts

26th pct

Shareholder dilution

-1.4 pts

22th pct

Latest change (2026-08-04): 70 → 57 · ↓ Free cash flow 75→22; ↓ Revenue growth 93→79

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in TMDX

Events flagged as statistical outliers against TMDX's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-04
TMDX quality score dropped 14 points (70→56) on a new filing
View source filing →

TMDX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for TransMedics Group, Inc. (TMDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TMDX at 67.2/100 on a 32-signal composite quality model, placing it at rank #377 of 2,961 stocks — the top 25% of the AI-ranked universe. TMDX scores in the top quartile across revenue growth (92.1), balance sheet strength (90.2), profitability (86.4). Areas of concern include institutional flow (25.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TransMedics Group, Inc. reports quarterly revenue of $189.9M, net income of $14.7M, an operating margin of 12.5%. Top institutional holders of TMDX by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. TMDX trades on the Nasdaq exchange and files with the SEC under CIK 1756262. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TMDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TransMedics Group, Inc. directly from SEC EDGAR. TransMedics Group, Inc.'s 13F Pro composite quality score has ranged between 21 and 73 since 2021, currently 67.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about TransMedics Group, Inc.

Quirks, history, and lore behind TMDX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Revenue has grown rapidly into the hundreds of millions of dollars, driven almost entirely by a single proprietary platform that charges per procedure.
3
The History
Founded in the 2000s, it spent years in near-obscurity developing technology to solve one of medicine's most brutal logistical problems: organs dying on the way to patients.
4
The Secret
Its system doesn't just keep donor organs on ice — it actually perfuses them with warm, oxygenated blood, keeping hearts, lungs, and livers essentially alive outside the body during transport.
5
The Lore
Its technology has meaningfully extended the viable transport window for donor organs, allowing transplant centers to accept organs from hospitals much farther away than was previously practical.
6
The Giveaway
Its Organ Care System is described as a "heart in a box" — a portable machine that keeps a donor heart beating outside the chest until it reaches the recipient.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving TMDX's Business? Latest 10-Q Breakdown

AI-extracted from TransMedics Group, Inc.'s 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue grew 21% YoY to $189.9M on service and Liver-driven product growth, but net income fell 58% YoY to $14.7M as R&D nearly doubled, interest expense rose on a new finance lease, and management disclosed a material weakness in inventory controls.

Biggest Revenue Drivers

Net product revenue$111.2M+16% YoY

Higher sales volumes of OCS Liver disposable sets

Service revenue$78.8M+29% YoY

Increased usage of the National OCS Program (organ procurement, perfusion management and transplant logistics)

Biggest Revenue Drivers

Total revenue: $189.9M+21% YoY

Net product revenue$111.2M+16% YoY

Higher sales volumes of OCS Liver disposable sets

Service revenue$78.8M+29% YoY

Increased usage of the National OCS Program (organ procurement, perfusion management and transplant logistics)

Largest Expense Items

Selling, general and administrative$57.8M+31% YoY

Higher personnel costs from team expansion, $4.6M increase in professional/consultant fees including transaction-related costs, and increased facility/IT and depreciation costs

Total cost of revenue$76.8M+26% YoY

Higher freight costs and temporary inventory-related costs including strategic stocking and clinical trial product costs

Margins: Overall gross margin declined to 60% from 61% YoY, driven by a higher mix of lower-margin service revenue and a drop in product gross margin to 77% from 80% due to higher freight and temporary inventory-related costs.

Watch Items from the Filing

Management concluded disclosure controls were not effective due to a material weakness in internal controls over inventory movement within the manufacturing network.
Securities class action (Jewik/Collins) alleging misstatements during a 2023-2025 class period is proceeding to discovery after the court partially denied a motion to dismiss on July 21, 2026; damages unspecified.
Interest expense rose to $7.2M from $3.5M YoY, including $3.8M of new imputed interest on a 18-year, $374.6M finance lease for the Somerville, MA headquarters commencing January 2026.
No single customer accounted for more than 10% of revenue or accounts receivable in the quarter, indicating low customer concentration risk.
New headquarters project carries estimated total capital expenditures of $200M-$240M through 2030, with $12.7M already contractually committed.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$189.9M

Net Income

Q2 2026

$14.7M

Free Cash Flow

Q2 2026

$10.2M

Operating Margin

Q2 2026

12.5%

ROIC

Q2 2026

17.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+37.1% YoY

$605.5MFY 2025

FY22 $93.5MFY23 $241.6MFY24 $441.5MFY25 $605.5M

Net Income

+436.6% YoY

$190.3MFY 2025

FY22 $-36.2MFY23 $-25.0MFY24 $35.5MFY25 $190.3M

Operating Income

+189.6% YoY

$108.6MFY 2025

FY22 $-31.4MFY23 $-28.7MFY24 $37.5MFY25 $108.6M

EPS (Diluted)

+382.2% YoY

$4.87FY 2025

FY22 $-1.23FY23 $-0.77FY24 $1.01FY25 $4.87

Total Assets

+32.9% YoY

$1.07BFY 2025

FY22 $277.1MFY23 $706.0MFY24 $804.1MFY25 $1.07B

Total Debt

$10.0MFY 2025

FY22 $58.7MFY23 —FY24 —FY25 $10.0M

Op. Cash Flow

+295.1% YoY

$192.8MFY 2025

FY22 $-45.8MFY23 $-13.0MFY24 $48.8MFY25 $192.8M

Free Cash Flow

+265.0% YoY

$133.6MFY 2025

FY22 $-57.7MFY23 $-164.9MFY24 $-80.9MFY25 $133.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$605.5M +37.1%	$441.5M +82.7%	$241.6M +158.5%	$93.5M +208.8%	$30.3M +18.0%	$25.6M
Net Income	$190.3M +436.6%	$35.5M +241.7%	$-25.0M +30.9%	$-36.2M +18.1%	$-44.2M -53.8%	$-28.7M
Operating Income	$108.6M +189.6%	$37.5M +230.5%	$-28.7M +8.6%	$-31.4M +20.3%	$-39.4M -49.4%	$-26.4M
EPS (Diluted)	$4.87 +382.2%	$1.01 +231.2%	$-0.77 +37.4%	$-1.23 +23.1%	$-1.60 -37.9%	$-1.16
Total Assets	$1.07B +32.9%	$804.1M +13.9%	$706.0M +154.8%	$277.1M +105.5%	$134.9M -11.3%	$152.0M
Total Debt	$10.0M	—	—	$58.7M +66.8%	$35.2M +1.6%	$34.7M
Operating Cash Flow	$192.8M +295.1%	$48.8M +474.6%	$-13.0M +71.6%	$-45.8M -58.7%	$-28.9M +4.6%	$-30.3M
Free Cash Flow	$133.6M +265.0%	$-80.9M +50.9%	$-164.9M -185.6%	$-57.7M -78.3%	$-32.4M -5.4%	$-30.7M

Get alerted when TMDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TransMedics Group, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TMDX

BlackRock, Inc.
$371.7M5,596,549 sh
FMR LLC
$341.0M5,133,328 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$128.5M1,933,989 sh
VANGUARD CAPITAL MANAGEMENT LLC
$99.5M1,497,600 sh
STATE STREET CORP
$94.3M1,420,421 sh
WOLVERINE ASSET MANAGEMENT LLC
$75.4M69,459,000 sh
TWO SIGMA INVESTMENTS, LP
$72.9M67,435,000 sh
TENOR CAPITAL MANAGEMENT Co., L.P.
$64.8M59,560,000 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$60.5M910,495 sh
GEODE CAPITAL MANAGEMENT, LLC
$59.5M894,913 sh

Fund	Value	Shares
BlackRock, Inc.	$371.7M	5,596,549
FMR LLC	$341.0M	5,133,328
VANGUARD PORTFOLIO MANAGEMENT LLC	$128.5M	1,933,989
VANGUARD CAPITAL MANAGEMENT LLC	$99.5M	1,497,600
STATE STREET CORP	$94.3M	1,420,421
WOLVERINE ASSET MANAGEMENT LLC	$75.4M	69,459,000
TWO SIGMA INVESTMENTS, LP	$72.9M	67,435,000
TENOR CAPITAL MANAGEMENT Co., L.P.	$64.8M	59,560,000
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$60.5M	910,495
GEODE CAPITAL MANAGEMENT, LLC	$59.5M	894,913

Companies Similar to TMDX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

LIVN

LivaNova PLC

AI score

Similar quality profile · 17 shared holders

Hood River Capital Management LLC EMERALD ADVISERS, LLC TENOR CAPITAL MANAGEMENT Co., L.P.

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 10 shared holders

BRAIDWELL LP NORDEA INVESTMENT MANAGEMENT AB Emerald Investment Advisers, LLC

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 11 shared holders

BROWN CAPITAL MANAGEMENT LLC NORDEA INVESTMENT MANAGEMENT AB ArrowMark Colorado Holdings LLC

LMAT

LEMAITRE VASCULAR INC

AI score

Similar quality profile · 10 shared holders

READYSTATE ASSET MANAGEMENT LP TENOR CAPITAL MANAGEMENT Co., L.P.CONGRESS ASSET MANAGEMENT CO /MA

INSP

Inspire Medical Systems, Inc.

AI score

Similar quality profile · 8 shared holders

BRAIDWELL LP BROWN CAPITAL MANAGEMENT LLC NORDEA INVESTMENT MANAGEMENT AB

VCEL

Vericel Corp

AI score

Similar quality profile · 10 shared holders

CONGRESS ASSET MANAGEMENT CO /MA FRONTIER CAPITAL MANAGEMENT CO LLC BROWN CAPITAL MANAGEMENT LLC

DXCM

DEXCOM INC

AI score

Similar quality profile · 13 shared holders

TENOR CAPITAL MANAGEMENT Co., L.P.EVENTIDE ASSET MANAGEMENT, LLC DeepCurrents Investment Group LLC

CDNA

CareDx, Inc.

AI score

Similar quality profile · 6 shared holders

BRAIDWELL LP Portolan Capital Management, LLC ArrowMark Colorado Holdings LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TMDX on your watchlist

Track score changes the day TransMedics Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TMDX a good stock to buy?

13F Pro's AI-powered analysis of TransMedics Group, Inc. (TMDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TMDX are available on the TMDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TMDX is classified as a mid company.

Which hedge funds own TMDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TMDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TransMedics Group, Inc.'s investment landscape.